Answers are grounded in this paper and cite their sources.
OBJECTIVE: The aim of the present study was to compare the efficacy and safety of drug‑eluting beads transarterial chemoembolization (DEB-TACE) with CalliSpheres® microspheres (CSM) combined with targeted therapy and immunotherapy and DEB-TACE with CSM in the treatment of intermediate-advanced hepatocellular carcinoma (HCC). METHODS: Ninety patients with HCC were divided into an experimental group (DEB-TACE combined with targeted therapy and immunotherapy, n=45) and a control group (DEB-TACE alone, n=45). The primary outcome measure was progression-free survival (PFS). Secondary measures included the disease control rate (DCR), objective response rate (ORR), and treatment-related adverse events. RESULTS: At the last follow-up, the median PFS of the experimental and control groups was 327 d (97.5 % CI, 116.3-731 d) and 200 d (97.5 % CI, 38.4-652.9 d), respectively. At 1, 3, 6, and 12 months after treatment, the ORR was 93.3 % and 77.8 %, 93.3 % and 71.1 %, 64.4 % and 40.0 %, and 35.6 % and 28.9 %, respectively, and the DCR was 100 % and 93.3 %, 97.8 % and 71.1 %, 66.7 % and 40.0 %, and 40.0 % and 28.9 %, respectively. Treatment-related adverse events after treatment were mainly grade 1-2, and all were alleviated after symptomatic treatment. CONCLUSION: Treatment response in intermediate-advanced HCC patients to DEB-TACE combined with targeted therapy and immunotherapy was associated with superior outcomes compared to DEB-TACE alone and the survival benefit was significant with an acceptable safety profile.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: